FindTrial
Sign In

A STUDY TO ASSESS THE LEVELS OF INTERLEUKIN-1ß IN SALIVA AFTER DIETARY SUPPLEMENTATION OF OMEGA-3 POLY UNSATURATED FATTY ACID (PUFA) IN PATIENTS WITH CHRONIC PERIODONTITIS AFTER SCALING AND ROOT PLANING – A RANDOMIZED CONTROL TRIAL

A CLINICO-IMMUNOLOGICAL STUDY TO ASSESS THE LEVELS OF SALIVARY INTERLEUKIN-1ß AFTER DIETARY SUPPLEMENTATION OF OMEGA-3 POLY UNSATURATED FATTY ACID (PUFA) AS AN ADJUNCT TO SCALING AND ROOT PLANING IN PATIENTS WITH CHRONIC PERIODONTITIS – A RANDOMIZED CONTROL TRIAL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/04/051986
Enrollment
16
Registered
2023-04-26
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K053- Chronic periodontitis

Interventions

Intervention1: Scaling and Root Planing alongwith dietary supplementation of Omega-3 Poly unsaturated fatty acids tablets: Dietary supplementation of Omega-3 poly unsaturated fatty acids as an adjunct

Sponsors

Ankit Krishna
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age between 18 to 60 years with non-gender specific participants 2. Systemically healthy patient 3. Patients suffering from generalized chronic periodontitis with = 30% of the sites showing = 4.0 mm of clinical attachment loss 4. Patients with at least 20 remaining teeth 5. Willing to comply with the study related procedures

Exclusion criteria

Exclusion criteria: 1. Chronic Smokers 2. Pregnant and Lactating women 3. Patients with any history of systemic diseases/conditions e.g. uncontrolled DM, chronic rheumatoid arthritis, steroid therapy, autoimmune diseases etc 4. Patient who have received treatment for periodontitis in the last 6 months 5. Patients on antibiotic therapy from past 1 month 6. Unwilling to participate in the study

Design outcomes

Primary

MeasureTime frame
To assess the levels of Interleukin-1ß (IL-1ß) in saliva before and after the treatmentTimepoint: Baseline, 3 months & 6 months—

Secondary

MeasureTime frame
To assess the following parameters: - • Plaque Index (PI) • Gingival Index (GI) • Bleeding Index (BI) • Probing Depth (PD) • Gain in Clinical Attachment Level (CAL)Timepoint: Baseline, 90 days, 180 days—

Countries

India

Contacts

Public ContactDr Ankit Krishna

Armed Forces Medical College

tprasanthavin@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026